# Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Oct 1, 2016

- Company: [Thermo Fisher Scientific Inc.](/companies/tmo.md) (CIK 97745)
- Form: 10-Q
- Filed: 2016-11-04
- Accepted by EDGAR: Nov 4, 2016, 12:09 ET
- Period: 2016-10-01
- Accession: 0000097745-16-000072
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/97745/000009774516000072/tmoq3201610q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/97745/000009774516000072/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-10-01.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-07-03 to 2016-10-01 | $4.49bn | us-gaap:Revenues |
| Revenue | 9 months, 2016-01-01 to 2016-10-01 | $13.32bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-07-03 to 2016-10-01 | $2.02bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2016-01-01 to 2016-10-01 | $6.00bn | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2016-07-03 to 2016-10-01 | $183.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2016-01-01 to 2016-10-01 | $542.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-07-03 to 2016-10-01 | $1.27bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-01-01 to 2016-10-01 | $3.71bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-07-03 to 2016-10-01 | $541.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-01 to 2016-10-01 | $1.70bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-07-03 to 2016-10-01 | $113.3m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-01-01 to 2016-10-01 | $338.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-07-03 to 2016-10-01 | −$45.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2016-01-01 to 2016-10-01 | −$20.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-07-03 to 2016-10-01 | $473.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months, 2016-01-01 to 2016-10-01 | $1.39bn | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2016-07-03 to 2016-10-01 | $1.19 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-10-01 | $3.50 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-07-03 to 2016-10-01 | $1.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-01-01 to 2016-10-01 | $3.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-07-03 to 2016-10-01 | 397,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2016-01-01 to 2016-10-01 | 397,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2016-01-01 to 2016-10-01 | $1.95bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-01-01 to 2016-10-01 | $310.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2016-01-01 to 2016-10-01 | $179.2m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2016-01-01 to 2016-10-01 | $1.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-10-01 | $1.97bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-10-01 | $8.20bn | us-gaap:AssetsCurrent |
| Total assets | at 2016-10-01 | $48.01bn | us-gaap:Assets |
| Current liabilities | at 2016-10-01 | $5.26bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | at 2016-10-01 | $1.97bn | us-gaap:DebtCurrent |
| Shareholders' equity | at 2016-10-01 | $21.66bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2016-10-01 | 395,025,225 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 48,201 characters.

Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 are made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this Quarterly Report.

A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading “Risk Factors” in Part II, Item 1A of this report on Form 10-Q.

### Overview

The company develops, manufactures and sells a broad range of products that are sold worldwide. The company expands the product lines and services it offers by developing and commercializing its own technologies and by making strategic acquisitions of complementary businesses. The company’s continuing operations fall into four business segments (see Note 3): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Services.

### Recent Acquisitions

The company’s strategy is to augment internal growth at existing businesses with complementary acquisitions. The company’s principal recent acquisitions and divestitures are described below.

On February 4, 2015, the company acquired Advanced Scientifics, Inc., a North America-based global provider of single-use technologies for customized bioprocessing solutions, for approximately $289 million. Advanced Scientifics was integrated into the Life Sciences Solutions segment and expands the company’s bioprocessing offerings. Revenues of Advanced Scientifics were approximately $80 million in 2014.

On September 30, 2015, the company acquired, within the Laboratory Products and Services segment, Alfa Aesar, a U.K.-based global manufacturer of research chemicals from Johnson Matthey Plc, for £257 million ($392 million) in cash. The acquisition expands the company’s existing portfolio of chemicals, solvents and reagents. Revenues of Alfa Aesar were approximately £78 million in 2014.

On March 31, 2016, the company acquired, within the Life Sciences Solutions segment, Affymetrix, Inc., a North America-based provider of cellular and genetic analysis products, for a total purchase price of $1.34 billion, net of cash acquired, including the assumption of $254 million of debt. The acquisition expands the company's existing portfolio of antibodies and assays for flow cytometry and single-cell biology applications. Additionally, the acquisition expands the company's genetic analysis portfolio through the addition of microarrays. Revenues of Affymetrix were $360 million in 2015.

On September 19, 2016, the company acquired, within the Analytical Instruments segment, FEI Company, a North America-based provider of high-performance electron microscopy, for a total purchase price of $4.08 billion, net of cash acquired. The acquisition strengthens the company's analytical instrument portfolio with the addition of high-end electron microscopes. Revenues of FEI were $930 million in 2015.

### Overview of Results of Operations and Liquidity

*(Dollars in millions)*

| Revenues | Three Months Ended October 1, 2016 |  | September 26, 2015 |  | Nine Months Ended October 1, 2016 |  | September 26, 2015 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Life Sciences Solutions | $1,231.5 | 27.4% | $1,080.4 | 26.2% | $3,642.1 | 27.3% | $3,229.6 | 26.2% |
| Analytical Instruments | 898.0 | 20.0% | 778.5 | 18.9% | 2,451.2 | 18.4% | 2,282.9 | 18.5% |
| Specialty Diagnostics | 798.9 | 17.8% | 776.9 | 18.8% | 2,504.8 | 18.8% | 2,379.2 | 19.3% |
| Laboratory Products and Services | 1,746.2 | 38.9% | 1,638.2 | 39.7% | 5,273.0 | 39.6% | 4,844.9 | 39.3% |
| Eliminations | (183.7) | (4.1)% | (150.8) | (3.6)% | (550.2) | (4.1)% | (423.7) | (3.3)% |
|  | $4,490.9 | 100% | $4,123.2 | 100% | $13,320.9 | 100% | $12,312.9 | 100% |

Sales in the third quarter of 2016 were $4.49 billion, an increase of $368 million from 2015. Sales increased $201 million due to acquisitions, net of divestitures. The unfavorable effects of currency translation resulted in a decrease in revenues of $13 million in the third quarter of 2016. Aside from the effects of acquisitions, divestitures and currency translation, revenues increased $179 million (4%) primarily due to increased demand in the fiscal quarter compared to the 2015 quarter. Demand from customers in pharmaceutical and biotech industries was particularly strong. Sales to customers in the company's primary end markets grew except for industrial and applied markets where sales decreased slightly. Sales growth was modest in North America, moderate in Europe and strong in Asia.

In the third quarter of 2016, total company operating income and operating income margin were $541 million and 12.0%, respectively, compared with $563 million and 13.7%, respectively, in 2015. The decrease in operating income was primarily due to higher restructuring and acquisition-related costs and, to a lesser extent, strategic growth investments, offset in part by productivity improvements, net of inflationary cost increases and profit on higher sales in local currencies. The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, focused research projects and other expenditures to enhance the customer experience. The company’s references throughout this discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system, reduced costs resulting from global sourcing initiatives, a lower cost structure following restructuring actions, including headcount reductions and consolidation of facilities, and low cost region manufacturing.

The company recorded a $46 million benefit from income taxes in the third quarter of 2016 including discrete benefits totaling $39 million, or 9.1 percentage points, related to prior year tax filings. The tax provision in the third quarter of 2016 was also favorably affected by $9 million, or 2.0 percentage points, as a result of adjustments to deferred tax balances due to changes in tax rates. The company expects its effective tax rate for all of 2016 will be less than 2% based on currently forecasted rates of profitability in the countries in which the company conducts business. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting purposes and are expected to total $630 to $700 million in 2016. The company recorded a $9 million benefit from income taxes in the third quarter of 2015 including discrete benefits totaling $44 million related to additional prior year foreign tax and other credits as well as restructuring and other costs associated with the 2014 acquisition of Life Technologies. The effective rate in both periods was also affected by relatively significant earnings in lower tax jurisdictions.

Income from continuing operations decreased to $474 million in the third quarter of 2016, from $477 million in the third quarter of 2015 due to i) the decrease in operating income in the 2016 period (discussed above), ii) an increase in interest expense due to increases in outstanding debt and effective interest rates and iii) charges related to obtaining bridge financing for the pending acquisition of FEI. These decreases were substantially offset by an increase in the income tax benefit in the 2016 period (discussed above),

During the first nine months of 2016, the company’s cash flow from operations totaled $1.95 billion compared with $1.59 billion for 2015. The increase primarily resulted from lower investments in working capital in the 2016 period.

As of October 1, 2016, the company’s short-term debt totaled $1.97 billion, including $0.90 billion of senior notes, which were repaid in October 2016, $250 million due within the next twelve months under a 3-year term loan agreement and $821 million of commercial paper obligations. The company has a revolving credit facility with a bank group that provides up to

### Overview of Results of Operations and Liquidity (continued)

$2.50 billion of unsecured multi-currency revolving credit. If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of October 1, 2016, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by approximately $67 million as a result of outstanding letters of credit.

The company believes that its existing cash and cash equivalents of $1.97 billion as of October 1, 2016 and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to fund the debt repayment made in October 2016 and to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

### Critical Accounting Policies and Estimates

The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to bad debts, inventories, business combinations, intangible assets and goodwill, sales returns, income taxes, contingencies and litigation, and pension costs. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Form 10-K for 2015, describe the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no significant changes in the company's critical accounting policies during the first nine months of 2016.

### Results of Operations

### Third Quarter 2016 Compared With Third Quarter 2015

*(In millions)*

| Revenues | Three Months Ended October 1, 2016 | September 26, 2015 | Total Change | Currency Translation | Acquisitions/ Divestitures | Operations |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Life Sciences Solutions | $1,231.5 | $1,080.4 | $151.1 | $(0.9) | $75.9 | $76.1 |
| Analytical Instruments | 898.0 | 778.5 | 119.5 | (0.3) | 98.8 | 21.0 |
| Specialty Diagnostics | 798.9 | 776.9 | 22.0 | (1.5) | — | 23.5 |
| Laboratory Products and Services | 1,746.2 | 1,638.2 | 108.0 | (14.3) | 28.2 | 94.1 |
| Eliminations | (183.7) | (150.8) | (32.9) | 4.1 | (1.6) | (35.4) |
| Consolidated Revenues | $4,490.9 | $4,123.2 | $367.7 | $(12.9) | $201.3 | $179.3 |

Sales in the third quarter of 2016 were $4.49 billion, an increase of $368 million from the third quarter of 2015. Sales increased $201 million due to acquisitions, net of divestitures. The unfavorable effects of currency translation resulted in a decrease in revenues of $13 million in 2016. Aside from the effects of acquisitions/divestitures and currency translation, revenues increased $179 million (4%) primarily due to increased demand in the fiscal quarter compared to the 2015 quarter. Demand from customers in pharmaceutical and biotech industries was particularly strong. Sales to customers in the company's primary end markets grew except for industrial and applied markets where sales decreased slightly. Sales growth was modest in North America, moderate in Europe and strong in Asia.

In the third quarter of 2016, total company operating income and operating income margin were $541 million and 12.0%, respectively, compared with $563 million and 13.7%, respectively, in 2015. The decrease in operating income was primarily due to higher restructuring and acquisition-related costs and, to a lesser extent, strategic growth investments, offset in part by productivity improvements, net of inflationary cost increases and profit on higher sales in local currencies.

In the third quarter of 2016, the company recorded restructuring and other costs, net, of $150 million, including $32 million of charges to cost of revenues for the sale of inventories revalued at the date of acquisition and to conform the accounting policies of FEI with the company's accounting policies. The company recorded $63 million of charges to selling, general and administrative expenses, primarily for third-party transaction costs related to the acquisitions of FEI and Affymetrix as well as product liability litigation. In addition, the company recorded $45 million of cash restructuring costs, primarily to achieve acquisition synergies, including severance and abandoned facilities costs associated with the closure and consolidation of facilities in the U.S. The company’s other businesses incurred costs for continued headcount reductions and facility consolidations in an effort to streamline operations including severance at several businesses and abandoned facility expenses at businesses that have been or are being consolidated in the U.S., Europe and Asia. The company also recorded $10 million of other charges, net, principally associated with litigation-related matters (see Note 14).

In the third quarter of 2015, the company recorded restructuring and other costs, net, of $41 million primarily for charges associated with product liability litigation and costs of streamlining operations, including severance and other costs associated with headcount reductions at several businesses. These charges also were for actions to achieve synergies from the Life Technologies acquisition.

As of November 4, 2016, the company has identified restructuring actions that will result in additional charges of approximately $70 million in 2016 and 2017, and expects to identify additional actions during 2016 which will be recorded when specified criteria are met, such as communication of benefit arrangements and abandonment of leased facilities.

#### Segment Results

The company’s management evaluates segment operating performance using operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition-related activities; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitate comparison of performance for determining compensation (Note 3). Accordingly, the following segment data is reported on this basis.

### Results of Operations (continued)

*(Dollars in millions)*

| Revenues | Three Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Life Sciences Solutions | $1,231.5 | $1,080.4 | 14% |
| Analytical Instruments | 898.0 | 778.5 | 15% |
| Specialty Diagnostics | 798.9 | 776.9 | 3% |
| Laboratory Products and Services | 1,746.2 | 1,638.2 | 7% |
| Eliminations | (183.7) | (150.8) | 22% |
| Consolidated Revenues | $4,490.9 | $4,123.2 | 9% |
| **Segment Income** |  |  |  |
| Life Sciences Solutions | $370.1 | $332.7 | 11% |
| Analytical Instruments | 190.1 | 146.5 | 30% |
| Specialty Diagnostics | 214.4 | 204.9 | 5% |
| Laboratory Products and Services | 257.9 | 249.6 | 3% |
| Subtotal Reportable Segments | 1,032.5 | 933.7 | 11% |
| Cost of Revenues Charges | (32.4) | (0.8) |  |
| Selling, General and Administrative Charges, Net | (62.5) | (24.6) |  |
| Restructuring and Other Costs, Net | (54.9) | (15.5) |  |
| Amortization of Acquisition-related Intangible Assets | (341.6) | (329.9) |  |
| Consolidated Operating Income | $541.1 | $562.9 | (4)% |
| Reportable Segments Operating Income Margin | 23.0% | 22.6% |  |
| Consolidated Operating Income Margin | 12.0% | 13.7% |  |

Income from the company’s reportable segments increased 11% to $1.03 billion in the third quarter of 2016 due primarily to productivity improvements, net of inflationary cost increases and profit on higher sales in local currencies. These increases were offset in part by strategic growth investments and unfavorable sales mix.

#### Life Sciences Solutions

*(Dollars in millions)*

|  | Three Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $1,231.5 | $1,080.4 | 14% |
| Operating Income Margin | 30.1% | 30.8% | -0.7 pt |

Sales in the Life Sciences Solutions segment increased $151 million to $1.23 billion in the third quarter of 2016. Sales increased $76 million (7%) due to higher revenues at existing businesses and $76 million due to an acquisition, offset in part by a decrease of $1 million due to the unfavorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for bioprocess production products as well as biosciences products and next generation sequencing offerings.

Operating income margin was 30.1% in the third quarter of 2016 compared to 30.8% in the third quarter of 2015. The decrease resulted primarily from unfavorable sales mix, acquisition dilution and strategic growth investments, offset in part by productivity improvements, net of inflationary cost increases and, to a lesser extent, profit on higher sales in local currencies.

#### Analytical Instruments

*(Dollars in millions)*

|  | Three Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $898.0 | $778.5 | 15% |
| Operating Income Margin | 21.2% | 18.8% | 2.4 pt |

Sales in the Analytical Instruments segment increased $120 million to $898 million in the third quarter of 2016. Sales increased $99 million due to acquisitions and $21 million (3%) due to higher revenues at existing businesses. The increase in revenue at existing businesses was primarily due to increased demand for products sold by the segment's chromatography and mass spectrometry business and, to a lesser extent, by its environmental instruments business. These increases were offset in part by lower sales of chemical analysis products due primarily to softness in certain industrial end markets.

Operating income margin was 21.2% in the third quarter of 2016 compared to 18.8% in the third quarter of 2015. The increase resulted primarily from productivity improvements, net of inflationary cost increases and, to a lesser extent, favorable foreign currency exchange and the effect of acquisitions, offset in part by unfavorable sales mix and strategic growth investments.

#### Specialty Diagnostics

*(Dollars in millions)*

|  | Three Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $798.9 | $776.9 | 3% |
| Operating Income Margin | 26.8% | 26.4% | 0.4 pt |

Sales in the Specialty Diagnostics segment increased $22 million to $799 million in the third quarter of 2016. Sales increased $24 million (3%) due to higher revenues at existing businesses, offset in part by a decrease of $2 million due to the unfavorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for products sold through the segment’s healthcare market channel and transplant diagnostics products.

Operating income margin was 26.8% in the third quarter of 2016 and 26.4% in the third quarter of 2015. The increase resulted primarily from productivity improvements, net of inflationary cost increases and, to a lesser extent, profit on higher sales in local currencies and favorable foreign currency exchange, offset in part by strategic growth investments.

#### Laboratory Products and Services

*(Dollars in millions)*

|  | Three Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $1,746.2 | $1,638.2 | 7% |
| Operating Income Margin | 14.8% | 15.2% | -0.4 pt |

Sales in the Laboratory Products and Services segment increased $108 million to $1.75 billion in the third quarter of 2016. Sales increased $94 million (6%) due to higher revenues at existing businesses and $28 million due to an acquisition. These increases were offset in part by $14 million due to the unfavorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for products sold through the segment's channel business as well as clinical trial logistics services.

Operating income margin was 14.8% in the third quarter of 2016 and 15.2% in the third quarter of 2015. The decrease was primarily due to unfavorable sales mix and strategic growth investments, offset in part by productivity improvements, net of inflationary cost increases and, to a lesser extent, profit on higher sales in local currencies.

#### Other Expense, Net

The company reported other expense, net, of $113 million and $95 million in the third quarter of 2016 and 2015, respectively (Note 4). Interest expense increased $13 million primarily due to increases in outstanding debt to fund acquisitions. In 2016, other items, net includes $12 million of charges related to the amortization of fees paid to obtain bridge financing commitments for the acquisition of FEI. In 2015, other items, net includes a $3 million loss on the early extinguishment of debt.

#### Provision for Income Taxes

The company recorded a $46 million benefit from income taxes in the third quarter of 2016 including discrete benefits totaling $39 million, or 9.1 percentage points, related to prior year tax filings. The tax provision in the third quarter of 2016 was also favorably affected by $9 million, or 2.0 percentage points, as a result of adjustments to deferred tax balances due to changes in tax rates. The company expects its effective tax rate for all of 2016 will be less than 2% based on currently forecasted rates of profitability in the countries in which the company conducts business. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting purposes and are expected to total $630 to $700 million in 2016. The company recorded a $9 million benefit from income taxes in the third quarter of 2015 including discrete benefits totaling $44 million related to additional prior year foreign tax and other credits as well as restructuring and other costs associated with the 2014 acquisition of Life Technologies. The effective rate in both periods was also affected by relatively significant earnings in lower tax jurisdictions.

The company has operations and a taxable presence in approximately 50 countries outside the U.S. All of these countries except one have a lower tax rate than the U.S. The countries in which the company has a material presence that have significantly lower tax rates than the U.S. include Germany, the Netherlands, Singapore, Sweden, Switzerland and the United Kingdom. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.

### First Nine Months of 2016 Compared With First Nine Months of 2015

*(In millions)*

| Revenues | Nine Months Ended October 1, 2016 | September 26, 2015 | Total Change | Currency Translation | Acquisitions/ Divestitures | Operations |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Life Sciences Solutions | $3,642.1 | $3,229.6 | $412.5 | $(23.5) | $169.8 | $266.2 |
| Analytical Instruments | 2,451.2 | 2,282.9 | 168.3 | (14.0) | 99.1 | 83.2 |
| Specialty Diagnostics | 2,504.8 | 2,379.2 | 125.6 | (11.2) | (0.7) | 137.5 |
| Laboratory Products and Services | 5,273.0 | 4,844.9 | 428.1 | (49.8) | 89.3 | 388.6 |
| Eliminations | (550.2) | (423.7) | (126.5) | 8.3 | (3.3) | (131.5) |
| Consolidated Revenues | $13,320.9 | $12,312.9 | $1,008.0 | $(90.2) | $354.2 | $744.0 |

Sales in the first nine months of 2016 were $13.32 billion, an increase of $1.01 billion from the first nine months of 2015. Sales increased $354 million due to acquisitions. The unfavorable effects of currency translation resulted in a decrease in revenues of $90 million in 2016. Aside from the effects of currency translation and acquisitions, revenues increased $744 million (6%) primarily due to increased demand and four extra selling days in the first quarter compared to the 2015 quarter. (The company's fourth quarter of 2016 will have four fewer selling days than the corresponding 2015 quarter.) Sales to customers in the company’s primary end markets grew. Demand from customers in pharmaceutical and biotech industries was particularly strong. Sales growth was strong in each of the company's primary geographic regions.

In the first nine months of 2016, total company operating income and operating income margin were $1.70 billion and 12.7%, respectively, compared with $1.65 billion and 13.4%, respectively, in the first nine months of 2015. The increase in operating income was primarily due to productivity improvements, net of inflationary cost increases and profit on higher sales in local currencies. These increases were offset in part by higher restructuring and acquisition-related charges in the 2016 period, strategic growth investments and unfavorable sales mix.

In the first nine months of 2016, the company recorded restructuring and other costs, net, of $297 million, including $60 million of charges to cost of revenues for the sale of inventories revalued at the date of acquisition and to conform the accounting policies of FEI and Affymetrix with the company's accounting policies; $95 million of charges to selling, general and administrative expenses primarily for third-party transaction and integration costs related to the acquisitions of FEI and Affymetrix. In addition, the company recorded $136 million of cash restructuring costs, primarily to achieve acquisition synergies, including severance and abandoned facilities costs associated with the closure and consolidation of facilities in the U.S. The company’s other businesses incurred costs for continued headcount reductions and facility consolidations in an effort to streamline operations, including severance at several businesses and abandoned facility expenses at businesses that have been or are being consolidated in the U.S., Europe and Asia (see Note 14).

In the first nine months of 2015, the company recorded restructuring and other costs, net, of $106 million, including $3 million of charges to cost of revenues for accelerated depreciation at facilities closing due to real estate consolidation and the sale of inventories revalued at the date of acquisition; $35 million of charges to selling, general and administrative expenses primarily for charges associated with product liability litigation, third-party transaction and integration costs related to the acquisitions of Life Technologies and Alfa Aesar, and, to a lesser extent, accelerated depreciation at facilities closing due to real estate consolidation. In addition, the company recorded $66 million of cash restructuring costs primarily for actions to achieve synergies from the Life Technologies acquisition and for abandoned facilities costs associated with a manufacturing facility in the U.S. The company’s other businesses incurred costs for continued headcount reductions and facility consolidations in an effort to streamline operations, including severance at several businesses and abandoned facility expenses at businesses that have been or are being consolidated, including the consolidation of operations within several facilities in the U.S., Europe and Asia. The company also recorded charges for litigation-related matters associated with acquired and divested businesses. These costs were partially offset by gains on the sale of a small product line and real estate.

#### Segment Results

*(Dollars in millions)*

| Revenues | Nine Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Life Sciences Solutions | $3,642.1 | $3,229.6 | 13% |
| Analytical Instruments | 2,451.2 | 2,282.9 | 7% |
| Specialty Diagnostics | 2,504.8 | 2,379.2 | 5% |
| Laboratory Products and Services | 5,273.0 | 4,844.9 | 9% |
| Eliminations | (550.2) | (423.7) | 30% |
| Consolidated Revenues | $13,320.9 | $12,312.9 | 8% |
| **Segment Income** |  |  |  |
| Life Sciences Solutions | $1,069.7 | $954.9 | 12% |
| Analytical Instruments | 446.7 | 407.8 | 10% |
| Specialty Diagnostics | 682.4 | 646.2 | 6% |
| Laboratory Products and Services | 795.9 | 731.7 | 9% |
| Subtotal Reportable Segments | 2,994.7 | 2,740.6 | 9% |
| Cost of Revenues Charges | (60.4) | (2.5) |  |
| Selling, General and Administrative Charges, Net | (95.2) | (35.4) |  |
| Restructuring and Other Costs, Net | (140.9) | (67.9) |  |
| Amortization of Acquisition-related Intangible Assets | (1,001.6) | (988.8) |  |
| Consolidated Operating Income | $1,696.6 | $1,646.0 | 3% |
| Reportable Segments Operating Income Margin | 22.5% | 22.3% |  |
| Consolidated Operating Income Margin | 12.7% | 13.4% |  |

Income from the company’s reportable segments increased 9% to $2.99 billion in the first nine months of 2016 due primarily to productivity improvements, net of inflationary cost increases and profit on higher sales in local currencies. These increases were offset in part by strategic growth investments and unfavorable sales mix. The impact of having four extra selling days in the 2016 first quarter versus the 2015 first quarter benefited revenues for the company’s segments, particularly those with higher levels of consumables sales. In segments with a lower relative mix of consumable revenues, the extra days had a negative effect on operating margins, however, as the incremental revenues were less than the quarter’s daily average revenues while fixed costs were incurred irrespective of the level of incremental revenues from extra days in the quarter. The company expects a corresponding opposite effect in the fourth quarter of 2016 which has four fewer selling days than the fourth quarter of 2015.

#### Life Sciences Solutions

*(Dollars in millions)*

|  | Nine Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $3,642.1 | $3,229.6 | 13% |
| Operating Income Margin | 29.4% | 29.6% | -0.2 pt |

38

Sales in the Life Sciences Solutions segment increased $413 million to $3.64 billion in the first nine months of 2016. Sales increased $266 million (8%) due to higher revenues at existing businesses and $170 million due to acquisitions, offset in part by a decrease of $24 million due to the unfavorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for bioprocess production products and biosciences products as well as four extra selling days in the first quarter of 2016.

Operating income margin was 29.4% in the first nine months of 2016 compared to 29.6% in the first nine months of 2015. The decrease in operating margin resulted from unfavorable sales mix, acquisition dilution and strategic growth investments, offset by productivity improvements, net of inflationary cost increases and, to a lesser extent, profit on higher sales in local currencies.

#### Analytical Instruments

*(Dollars in millions)*

|  | Nine Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $2,451.2 | $2,282.9 | 7% |
| Operating Income Margin | 18.2% | 17.9% | 0.3 pt |

Sales in the Analytical Instruments segment increased $168 million to $2.45 billion in the first nine months of 2016. Sales increased $99 million due to acquisitions and $83 million (4%) due to higher revenues at existing businesses, offset in part by a decrease of $14 million due to the unfavorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for products sold by the segment's chromatography and mass spectrometry business and, to a lesser extent, sales of service offerings by its environmental instruments business. These increases were offset in part by lower sales of chemical analysis products due primarily to softness in certain industrial end markets.

Operating income margin was 18.2% in the first nine months of 2016 compared to 17.9% in the first nine months of 2015. The increase resulted primarily from profit on higher sales in local currencies and productivity improvements, net of inflationary cost increases, offset in part by unfavorable sales mix, strategic growth investments and higher costs from four additional selling days in the first quarter of 2016.

#### Specialty Diagnostics

*(Dollars in millions)*

|  | Nine Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $2,504.8 | $2,379.2 | 5% |
| Operating Income Margin | 27.2% | 27.2% | 0.0 pt |

Sales in the Specialty Diagnostics segment increased $126 million to $2.50 billion in the first nine months of 2016. Sales increased $138 million (6%) due to higher revenues at existing businesses, offset in part by decreases of $11 million due to the unfavorable effects of currency translation and $1 million due to a divestiture. The increase in revenue at existing businesses was primarily due to increased demand for products sold through the segment’s healthcare market channel, immunodiagnostics products and clinical diagnostics products as well as four extra selling days in the first quarter of 2016.

Operating income margin was 27.2% in both the first nine months of 2016 and the first nine months of 2015. Increases resulting primarily from profit on higher sales in local currencies and, to a lesser extent, productivity improvements, net of inflationary cost increase were offset by strategic growth investments and unfavorable sales mix.

#### Laboratory Products and Services

*(Dollars in millions)*

|  | Nine Months Ended October 1, 2016 | September 26, 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $5,273.0 | $4,844.9 | 9% |
| Operating Income Margin | 15.1% | 15.1% | 0.0 pt |

Sales in the Laboratory Products and Services segment increased $428 million to $5.27 billion in 2016. Sales increased $389 million (8%) due to higher revenues at existing businesses and $89 million due to an acquisition. These increases were offset in part by $50 million due to the unfavorable effects of currency translation. The increase in revenue at existing businesses was primarily due to increased demand for products in each of the segment’s principal businesses and four extra selling days in the first quarter of 2016.

Operating income margin was 15.1% in both the first nine months of 2016 and the first nine months of 2015. Increases resulting primarily from profit on higher sales in local currencies and productivity improvements, net of inflationary cost increases were offset by strategic growth investments, unfavorable sales mix and incremental costs associated with four extra selling days in the first quarter of 2016.

#### Other Expense, Net

The company reported other expense, net, of $325 million and $292 million in the first nine months of 2016 and 2015, respectively (Note 4). Interest expense increased $26 million primarily due to an increase in outstanding debt. In the first nine months of 2016, other items, net includes $22 million of charges related to the amortization of fees paid to obtain bridge financing commitments for the acquisition of FEI and $6.5 million of losses on the early extinguishment of debt, offset in part by $4 million of gains on investments. In 2015, other items, net includes costs of $7.5 million associated with entering into interest rate swap arrangements and a $6 million loss on the early extinguishment of debt.

#### Provision for Income Taxes

The company recorded a benefit from income taxes in the first nine months of 2016. In 2016, the company implemented tax planning initiatives related to non-U.S. subsidiaries. These non-U.S. subsidiaries incurred foreign tax obligations, and made cash and deemed distributions to the company’s U.S. operations which resulted in no net tax cost. As a result of these distributions, the company benefitted from U.S. foreign tax credits of $114 million, offset in part by additional U.S. taxes of $40 million on the related foreign income (which reduced the benefit from the foreign rate differential in 2016). The net benefit ($74 million) was a discrete item that reduced the company’s effective rate by 5.4 percentage points in the first nine months of 2016. The foreign tax credits are the result of foreign earnings remitted or deemed remitted to the U.S. during the reporting year and the U.S. treatment of taxes paid in the foreign jurisdictions in the years those profits were originally earned. The company intends to make similar types of distributions from non-U.S. subsidiaries in 2016 when they can be made at no net tax cost. The ability of the company to make distributions in future periods of similar type and magnitude will depend on the level of earnings and cash flow in various foreign jurisdictions and on the applicable tax laws in effect at that time. Accordingly, the impact of foreign tax credits on the company’s effective tax rate in future periods is likely to vary. In addition, the company recorded discrete benefits totaling $39 million, or 2.8 percentage points, related to prior year tax filings.

The company recorded a benefit from income taxes in the first nine months of 2015. In 2015, the company implemented tax planning initiatives related to non-U.S. subsidiaries. These initiatives resulted in additional foreign tax credits of $112 million, offset in part by additional U.S. income taxes of $39 million on the related foreign income (which reduced the benefit from the foreign rate differential in 2015). The net benefit ($73 million) was a discrete item that reduced the company’s effective rate by 5.4 percentage points in the first nine months of 2015. In addition, the company recorded discrete benefits totaling $51 million, or 3.8 percentage points, related to additional prior year foreign tax and other credits as well as restructuring and other costs associated with the 2014 acquisition of Life Technologies. The tax provision in the 2015 period was favorably affected by $13.5 million, or 1.0 percentage points, as a result of adjustments to deferred tax balances due to changes in tax rates. The effective rate in both periods was also affected by relatively significant earnings in lower tax jurisdictions.

### Recent Accounting Pronouncements

A description of recently issued accounting standards is included under the heading “*Recent Accounting Pronouncements”* in Note 1.

### Contingent Liabilities

The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current accrual estimates, if any, for one or more of the matters described under the headings “*Product Liability, Workers Compensation and Other Personal Injury Matters," "Intellectual Property Matters"* and *"Commercial Matters"* in Note 10 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.

### Liquidity and Capital Resources

Consolidated working capital was $2.94 billion at October 1, 2016, compared with $1.59 billion at December 31, 2015. Included in working capital were cash and cash equivalents of $1.97 billion at October 1, 2016 and $452 million at December 31, 2015. The increase in working capital is primarily due to the increase in cash. In October 2016, the company repaid $1.4 billion of debt obligations.

### First Nine Months of 2016

Cash provided by operating activities was $1.95 billion during the first nine months of 2016. An increase in accounts receivable used cash of $112 million primarily to support growth in sales in local currencies. An increase in other assets used cash of $92 million primarily due to the timing of payments. A decrease in other liabilities used cash of $194 million primarily due to the timing of payments for income taxes and incentive compensation. Cash payments for income taxes increased to $630 million during the first nine months of 2016, compared with $426 million in the first nine months of 2015. The company made cash contributions to its pension and postretirement benefit plans totaling $33 million during the first nine months of 2016. Payments for restructuring actions, principally severance costs and lease and other expenses of real estate consolidation, used cash of $62 million during the first nine months of 2016.

During the first nine months of 2016, the company’s investing activities used $5.44 billion of cash. Acquisitions used cash of $5.15 billion. The company’s investing activities also included the purchase of $311 million of property, plant and equipment.

The company’s financing activities provided $5.05 billion of cash during the first nine months of 2016. Issuance of senior notes and borrowings under term loans provided cash of $7.61 billion and an increase in commercial paper obligations provided cash of $769 million. Repayment of senior notes, the 364-day term loan and acquired debt used cash of $2.31 billion. The company’s financing activities also included the repurchase of $1.00 billion of the company’s common stock and the payment of $179 million in cash dividends, offset in part by $123 million of proceeds from employee stock option exercises. On July 7, 2016, the Board of Directors authorized the repurchase of up to $1.50 billion of the company’s common stock. At October 1, 2016, $1.50 billion was available for future repurchases of the company’s common stock under this authorization.

The company's commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments did not change materially between December 31, 2015 and October 1, 2016. The company expects that for all of 2016, expenditures for property, plant and equipment, net of disposals, will approximate $435 to $445 million.

As of October 1, 2016, the company’s short-term debt totaled $1.97 billion, including $0.90 billion of senior notes, which were repaid in October 2016, $250 million due within the next twelve months under a 3-year term loan agreement and $821 million of commercial paper obligations. The company has a revolving credit facility with a bank group that provides up to $2.50 billion of unsecured multi-currency revolving credit. If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of October 1, 2016, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by approximately $67 million as a result of outstanding letters of credit.

Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions and repayment of acquisition-related intercompany debt to the U.S. In addition, the company also transfers cash to the U.S. using non-taxable returns of capital as well as dividends where the related U.S. foreign tax credit equals or exceeds any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.

### Liquidity and Capital Resources (continued)

The company believes that its existing cash and cash equivalents of $1.97 billion as of October 1, 2016 and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to fund the debt repayment made in October 2016 and to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

### First Nine Months of 2015

Cash provided by operating activities was $1.59 billion during the first nine months of 2015. Increases in accounts receivable and inventories used cash of $146 million and $175 million, respectively, primarily to support growth in sales in local currencies. An increase in other assets used cash of $214 million primarily related to the timing of tax refunds. Other liabilities decreased by $236 million primarily due to the timing of payments for incentive compensation and income taxes. Cash payments for income taxes totaled $426 million. The company made cash contributions to its pension and postretirement benefit plans totaling $26 million during the first nine months of 2015. Payments for restructuring actions, principally severance costs and lease and other expenses of real estate consolidation, used cash of $79 million during the first three months of 2015.

During the first nine months of 2015, the company’s investing activities used $576 million of cash. Acquisitions used cash of $306 million. The company’s investing activities also included the purchase of $294 million of property, plant and equipment.

The company’s financing activities used $1.75 billion of cash during the first nine months of 2015. Repayments of long-term debt totaled $2.48 billion. Issuance of euro denominated senior notes provided cash of $543 million and an increase in commercial paper obligations provided cash of $726 million. The company’s financing activities also included the repurchase of $500 million of the company's common stock and the payment of $181 million in cash dividends, offset in part by $97 million of proceeds from employee stock option exercises.

## Market risk

As filed, 159 characters.

The company's exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure at year-end 2015.

## Controls and procedures

As filed, 2,113 characters.

#### Management’s Evaluation of Disclosure Controls and Procedures

The company’s management, with the participation of the company’s chief executive officer and chief financial officer, evaluated the effectiveness of the company’s disclosure controls and procedures as of October 1, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of the company’s disclosure controls and procedures as of October 1, 2016, the company’s chief executive officer and chief financial officer concluded that, as of such date, the company’s disclosure controls and procedures were effective at the reasonable assurance level.

#### Changes in Internal Control over Financial Reporting

There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended October 1, 2016, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.

## Risk factors

As filed, 30,415 characters.

Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements beginning on page 30.

*We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive.* Our growth strategy includes significant investment in and expenditures for product development. We sell our products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers’ requirements than we can. Without the timely introduction of new products, services and enhancements, our products and services will likely become technologically obsolete over time, in which case our revenue and operating results would suffer.

Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing at the technological, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their own products. As a result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail to adequately predict our customers’ needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenue.

*It may be difficult for us to implement our strategies for improving internal growth.* Some of the markets in which we compete have been flat or declining over the past several years. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:

- strengthening our presence in selected geographic markets;
- allocating research and development funding to products with higher growth prospects;
- developing new applications for our technologies;
- expanding our service offerings;
- continuing key customer initiatives;
- combining sales and marketing operations in appropriate markets to compete more effectively;
- finding new markets for our products; and
- continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.

We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.

*Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate.* Our business is affected by general economic conditions, both inside and outside the U.S. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key markets, are unstable, it could adversely affect the business, results of operations and financial condition of the company and its customers, distributors, and suppliers, having the effect of

- reducing demand for some of our products;
- increasing the rate of order cancellations or delays;
- increasing the risk of excess and obsolete inventories;
- increasing pressure on the prices for our products and services; and
- creating longer sales cycles and greater difficulty in collecting sales proceeds.

For example, recent developments in Europe have created uncertainty with respect to the ability of certain European countries to continue to service their sovereign debt obligations. This debt crisis could result in customers in Europe taking longer to pay for products they have purchased from us, or being unable to pay at all. The continued weakness in world economies makes the strength and timing of any economic recovery uncertain, and there can be no assurance that global economic conditions will not deteriorate further.

*Demand for some of our products depends on capital spending policies of our customers and on government funding policies.* Our customers include pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources and product and economic cycles, have a significant effect on the capital spending policies of these entities.

Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending. In fiscal year 2013, the U.S. Government was unable to reach agreement on budget reduction measures required by the Budget Control Act of 2011. As a result, in early 2013, an enforcement mechanism known as sequestration went into effect, which triggered one year of budget reductions. In subsequent years, statutory spending caps have constrained federal funding levels. Despite agreement not to impose similar cuts in fiscal years 2014 through 2017, it is possible that Congress will allow similar cuts to occur again in fiscal year 2018 and beyond.

*As a multinational corporation, we are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations.* International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (the “functional currency”). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. Should our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In the first nine months of 2016, currency translation had an unfavorable effect of $90 million on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.

*The approval of the Brexit Referendum in the United Kingdom may have an adverse impact on our results of operations.* In a referendum vote held on June 23, 2016, the United Kingdom voted to leave the European Union. In 2015, 4.6% of our revenues came from sales to the United Kingdom, which is our second largest market in Europe. The announcement of Brexit adversely impacted global markets, including currencies, and resulted in a sharp decline in the value of the British pound, as compared to the U.S. dollar and other currencies. The announcement of Brexit may create further global economic uncertainty, which may cause our customers in the U.K. and elsewhere to closely monitor their costs and reduce their spending budget on our products and services.

*Healthcare reform legislation could adversely impact us.* The Patient Protection and Affordable Care Act could have an adverse impact on us. Some of the potential consequences, such as a reduction in governmental support of healthcare services or adverse changes to the delivery or pricing of healthcare services or products or mandated benefits, may cause healthcare-industry participants to purchase fewer of our products and services or to reduce the prices they are willing to pay for our products or services.

*Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result.* We place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain and enforce patent protection for our products both in the United States and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially adversely affect our business and results of operations.

We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our collaborators, employees and consultants. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.

Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. With our acquisition of Life Technologies, we became party to several lawsuits in which plaintiffs claim we infringe their intellectual property (Note 10). We could incur substantial costs and diversion of management resources in defending these claims, which could have a material adverse effect on our business, financial condition and results of operations. In addition, parties making these claims could secure a judgment awarding substantial damages, as well as injunctive or other equitable relief, which could effectively block our ability to make, use, sell, distribute, or market our products and services in the United States or abroad. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.

*Changes in governmental regulations may reduce demand for our products or increase our expenses.* We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s regulation of the drug discovery and development process could have an adverse effect on the demand for these products.

*If our security products do not operate as designed and fail to detect explosives or radiation, we could be exposed to product liability and related claims for which we may not have adequate insurance coverage.* Products currently or previously sold by our environmental and process instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product liability claims. There are also many other factors beyond our control that could lead to liability claims, such as the reliability and competence of the customers’ operators and the training of such operators. Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities in excess of our insurance coverage. Although we carry product liability insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.

*Our inability to complete pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business.* Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.

Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible assets (primarily tradenames) on our balance sheet, which amount to approximately $21.58 billion and $1.35 billion, respectively, as of October 1, 2016. In addition, we have definite-lived intangible assets totaling $13.18 billion as of October 1, 2016. We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these businesses.

If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.

*We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenue associated with these customers.* We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

*Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us.* Our largest customer in the laboratory products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our large third-party suppliers abruptly discontinues selling products to us.

*Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.* We ship a significant portion of our products to our customers through independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.

*We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies.* For example, some of our operations are subject to regulation by the U.S. Food and Drug Administration and similar international agencies. These regulations govern a wide variety of product activities, from design and development to labeling, manufacturing, promotion, sales and distribution. If we fail to comply with the U.S. Food and Drug Administration’s regulations or those of similar international agencies, we may have to recall products and/or cease their manufacture and distribution, which would increase our costs and reduce our revenues.

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products, the handling, transportation and manufacture of substances that could be classified as hazardous, and our business practices in the U.S. and abroad such as anti-corruption and anti-competition laws. A failure to comply with these laws and regulations could result in criminal, civil and administrative penalties.

*Regulations related to “conflict minerals” may cause us to incur additional expenses and could limit the supply and increase the cost of certain metals used in manufacturing our products.* In 2012 the SEC adopted a rule requiring disclosures by public companies of specified minerals, known as conflict minerals, that are necessary to the functionality or production of products manufactured or contracted to be manufactured. The rule requires an annual disclosure report to be filed, and requires companies to perform due diligence and disclose and report whether or not such minerals originate from the Democratic Republic of Congo or an adjoining country. The rule could affect sourcing at competitive prices and availability in sufficient quantities of certain minerals used in the manufacture of our products, including tantalum, tin, gold and tungsten. The number of suppliers who provide conflict-free minerals may be limited. In addition, there may be material costs associated with complying with the disclosure requirements, such as costs related to determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we undertake, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.

*Our business could be adversely affected by disruptions at our sites.* We rely upon our manufacturing operations to produce many of the products we sell and our warehouse facilities to store products, pending sale. Any significant disruption of those operations for any reason, such as strikes or other labor unrest, power interruptions, fire, or other events beyond our control could adversely affect our sales and customer relationships and therefore adversely affect our business. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. Although most of our raw materials are available from a number of potential suppliers, our operations also depend upon our ability to obtain raw materials at reasonable prices. If we are unable to obtain the materials we need at a reasonable price, we may not be able to produce certain of our products or we may not be able to produce certain of these products at a marketable price, which could have an adverse effect on our results of operations.

*Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows.* As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.

*We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flow.* Our primary commodity exposures are for fuel, petroleum-based resins and steel. While we may seek to minimize the impact of price increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs.

*Unforeseen problems with the implementation and maintenance of our information systems could have an adverse effect on our operations*. As a part of our ongoing effort to upgrade our current information systems, we periodically implement new enterprise resource planning software and other software applications to manage certain of our business operations. As we implement and add functionality, problems could arise that we have not foreseen. Such problems could adversely impact our ability to provide quotes, take customer orders and otherwise run our business in a timely manner. In addition, if our new systems fail to provide accurate pricing and cost data our results of operations and cash flows could be adversely affected.

We also rely on our technology infrastructure, among other functions, to interact with suppliers, sell our products and services, fulfill orders and bill, collect and make payments, ship products, provide services and support to customers, track customers, fulfill contractual obligations and otherwise conduct business. Our systems may be vulnerable to damage or interruption from natural disasters, power loss, telecommunication failures, terrorist attacks, computer viruses, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. When we upgrade or change systems, we may suffer interruptions in service, loss of data or reduced functionality. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, interruptions in our services, which could harm our reputation and financial results.

*Our debt may restrict our investment opportunities or limit our activities.* As of October 1, 2016, we had approximately $18.91 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility that provides for up to $2.50 billion of unsecured multi-currency revolving credit. We may also obtain additional long-term debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.

Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.

Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures.

Additionally, the agreements governing our debt require that we maintain certain financial ratios, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities, make investments, create liens, sell assets and enter into transactions with affiliates. The covenants in our revolving credit facility and our term facility (each, a “Facility” and together, the “Facilities”) include a total debt-to-Consolidated EBITDA ratio and an interest coverage ratio. Specifically, the company has agreed that, so long as any lender has any commitment under the revolving credit facility, any letter of credit is outstanding under the revolving credit facility, or any loan or other obligation is outstanding under the revolving credit facility, it will not permit (as the following terms are defined in the credit agreement governing the revolving credit facility) the Consolidated Leverage Ratio (the ratio of consolidated Indebtedness to Consolidated EBITDA) to be greater than 4.5 to 1.0 as of the last day of any fiscal quarter for the first two consecutive quarters following the acquisition of FEI (see Note 2), with such ratio stepping down to 4.0 to 1.0 for the two immediately following fiscal quarters and then stepping down to 3.5 to 1.0 for each fiscal quarter thereafter. The company’s term facility includes Consolidated Leverage Ratio covenants substantively the same as the covenant included in the revolving credit facility.

The company has also agreed that so long as any lender has any commitment under the revolving credit facility or any letter of credit is outstanding under the revolving credit facility, or any loan or other obligation is outstanding under any Facility (including the term loan and bridge facilities), it will not permit the Consolidated Interest Coverage Ratio (the ratio of Consolidated EBITDA to Consolidated Interest Expense) to be less than 3.0 to 1.0 as at the last day of any fiscal quarter.

Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as foreign exchange rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default under other of our debt instruments.

Filed Nov 4, 2016.
Source: SEC EDGAR, the filing index for accession 0000097745-16-000072. Last ingested by Listed: Nov 14, 2026, 12:05 ET. No prices; not investment advice.
